European Release of EBV Assay for SmartCycler®
Quantitative Real-Time PCR Test for Epstein-Barr Virus Detection and Monitoring Allows Accurate Analysis and Improved Post Transplant Patient Management
Cepheid released the CE marked Smart EBV (Epstein-Barr Virus) Assay for clinical diagnostic use on the SmartCycler® System.
The EBV assay was released as a CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. Smart EBV is intended for rapid detection and quantitation of EBV viral load.
Patients with EBV related diseases often present with high levels of EBV in blood cells, serum or plasma which can be tracked over time. The Smart EBV assay offers a standardized method that can be used with all three of these types of specimens offering a wide dynamic range and highly sensitive limit of detection.
The use of an internal control greatly reduces the risk of false negative test results. The SmartCycler® System is a leading real-time PCR testing platform for hospitals, university research labs and government agencies. By automating the amplification and detection process, the SmartCycler System can deliver highly accurate and consistent test results from prepared biological samples in approximately 30-40 minutes.
With up to 96 independently programmable reaction sites, the SmartCycler can simultaneously run multiple experiments with different protocols and at different times. This eliminates complex advanced scheduling on larger, more costly systems as well as the need to transport samples to central facilities for analysis.
NOTE: This item is from our 'historic' database and may contain information which is not up to date.